U.S. referral execution gap offset by strong margin expansion and transformation savings.

FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.

Fresenius Medical Care is expanding its BEACON-US clinical initiative to build real-world evidence for high-volume hemodiafiltration therapy in the U.S. The program evaluates the 5008X CAREsystem and HVHDF across large patient populations, with data indicating fewer hospitalizations and improved survival outcomes. These findings point to potential gains in patient care quality and healthcare system efficiency as the therapy is more widely adopted. For investors tracking XTRA:FME, the...

Fresenius Medical Care stock has recovered modestly in the short term yet is still down about 30% over the past five years, while recent valuation checks suggest the market may be pricing it on the cheap side rather than as a fully valued turnaround story. The share price has declined 29.6% over five years, which points to a company that has struggled to create positive long term returns for shareholders. Recent progress in patient care technology and leadership changes can support sentiment...

Fresenius Medical Care (XTRA:FME) has drawn fresh attention after the Supervisory Board appointed Cassie McLean as Management Board member and Chief Executive Officer of the Care Delivery segment, reshaping leadership oversight of its global clinic operations. See our latest analysis for Fresenius Medical Care. The leadership change at Fresenius Medical Care comes just after a Q2 report where solid operating income and organic growth were followed by a sharp 1 day share price decline of...

Moby summary of Fresenius Medical Care AG & Co. KGaA's Q2 2026 earnings call

FMS delivers 23% operating income growth and margin expansion, while navigating US referral headwinds and TDAPA roll-off.

Fresenius Medical Care (NYSE:FMS) shares fell 8. 0% to €41.